Smithkline Beecham Corporation v. Abbott Laboratories

CourtCourt of Appeals for the Ninth Circuit
DecidedJanuary 21, 2014
Docket11-17357
StatusPublished

This text of Smithkline Beecham Corporation v. Abbott Laboratories (Smithkline Beecham Corporation v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Smithkline Beecham Corporation v. Abbott Laboratories, (9th Cir. 2014).

Opinion

FOR PUBLICATION

UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT

SMITHKLINE BEECHAM No. 11-17357 CORPORATION, DBA GlaxoSmithKline, D.C. No. Plaintiff-Appellee, 4:07-cv-05702-CW

v.

ABBOTT LABORATORIES, Defendant-Appellant.

SMITHKLINE BEECHAM No. 11-17373 CORPORATION, DBA GlaxoSmithKline, D.C. No. Plaintiff-Appellant, 4:07-cv-05702-CW

v. OPINION ABBOTT LABORATORIES, Defendant-Appellee.

Appeal from the United States District Court for the Northern District of California Claudia Wilken, Chief District Judge, Presiding

Argued and Submitted September 18, 2013—San Francisco, California 2 SMITHKLINE BEECHAM V. ABBOTT LABORATORIES

Filed January 21, 2014

Before: Mary M. Schroeder, Stephen Reinhardt, and Marsha S. Berzon, Circuit Judges.

Opinion by Judge Reinhardt

SUMMARY*

Jury Selection

Reversing the district court’s judgment in an antitrust case concerning a licensing agreement and the pricing of HIV medications, the panel held that classifications based on sexual orientation are subject to heightened scrutiny, and in jury selection, equal protection prohibits peremptory strikes based on sexual orientation.

The panel held that even though the Ninth Circuit had in the past applied rational basis review, United States v. Windsor, 133 S. Ct. 2675 (2013) (holding Defense of Marriage Act unconstitutional), required that heightened scrutiny be applied to equal protection claims involving sexual orientation. The panel held that in light of the history of exclusion of gays and lesbians from democratic institutions and the pervasiveness of stereotypes about the group, the protection of Batson v. Kentucky, 476 U.S. 79 (1986), applies, and equal protection forbids striking a juror on the basis of

* This summary constitutes no part of the opinion of the court. It has been prepared by court staff for the convenience of the reader. SMITHKLINE BEECHAM V. ABBOTT LABORATORIES 3

his sexual orientation. The panel remanded the case for a new trial.

COUNSEL

Daniel B. Levin (argued), Jeffrey I. Weinberger, Stuart N. Senator, Keith R.D. Hamilton, Kathryn A. Eidmann, Munger, Tolles, & Olson LLP, Los Angeles, California; Krista Enns, Winston & Strawn LLP, San Francisco, California; James F. Hurst, Samuel S. Park, Winston & Strawn LLP, Chicago, Illinois; Charles B. Klein, Steffen N. Johnson, Matthew A. Campbell, Jacob R. Loshin, Winston & Strawn LLP, Washington, D.C., for Defendant-Appellant/Cross-Appellee.

Lisa S. Blatt (argued), Sarah M. Harris, Arnold & Porter LLP, Washington, D.C.; Brian J. Hennigan (argued), Alexander F. Wiles, Carlos R. Moreno, Trevor V. Stockinger, Lillie A. Werner, Christopher Beatty, Andrew Ow, Irell & Manella LLP, Los Angeles, California; for Plaintiff-Appellee/Cross- Appellant.

Shelbi D. Day, Tara L. Borelli, Jon W. Davidson, Lambda Legal Defense and Education Fund, Inc., Los Angeles, California, for Amicus Curiae.

OPINION

REINHARDT, Circuit Judge:

The central question in this appeal arises out of a lawsuit brought by SmithKline Beecham (GSK) against Abbott Laboratories (Abbott) that contains antitrust, contract, and 4 SMITHKLINE BEECHAM V. ABBOTT LABORATORIES

unfair trade practice (UTPA) claims. The dispute relates to a licensing agreement and the pricing of HIV medications, the latter being a subject of considerable controversy in the gay community. GSK’s claims center on the contention that Abbott violated the implied covenant of good faith and fair dealing, the antitrust laws, and North Carolina’s Unfair Trade Practices Act by first licensing to GSK the authority to market an Abbott HIV drug in conjunction with one of its own and then increasing the price of the Abbott drug fourfold, so as to drive business to Abbott’s own, combination drug.

During jury selection, Abbott used its first peremptory strike against the only self-identified gay member of the venire. GSK challenged the strike under Batson v. Kentucky, 476 U.S. 79 (1986), arguing that it was impermissibly made on the basis of sexual orientation. The district judge denied the challenge.

This appeal’s central question is whether equal protection prohibits discrimination based on sexual orientation in jury selection. We must first decide whether classifications based on sexual orientation are subject to a standard higher than rational basis review. We hold that such classifications are subject to heightened scrutiny. We also hold that equal protection prohibits peremptory strikes based on sexual orientation and remand for a new trial.

I.

During jury selection, the district judge began by asking questions of the potential jurors based on their questionnaires, and then each party’s counsel had an opportunity to ask additional questions. When the judge turned her attention to SMITHKLINE BEECHAM V. ABBOTT LABORATORIES 5

Juror B, a male, she inquired first about his employment, as she had done with each of the previous members of the venire. Juror B stated that he worked as a computer technician for the Ninth Circuit Court of Appeals in San Francisco. During the course of the judge’s colloquy with Juror B, the juror revealed that his “partner” studied economics and investments. When the district judge followed up with additional questions, the prospective juror referred to his partner three times by using the masculine pronoun, “he,” and the judge subsequently referred to Juror B’s partner as “he” in a follow-up question regarding his employment status. Responding to additional questions from the judge, Juror B stated that he took an Abbott or a GSK medication and that he had friends with HIV. When the time arrived for Abbott’s counsel, Weinberger, to question Juror B, the questioning was brief and limited. Counsel’s first question concerned Juror B’s knowledge of the medications that were the focal point of the litigation: “You indicated that you know some people who have been diagnosed with HIV. . . . Do you know anything about the medications that any of them are on?” Juror B responded, “Not really.” Abbott’s counsel then continued: “Do you know whether any of them are taking any of the medications that we are going to be talking about here[,] . . . Norvir or Kaletra or Lexiva, any of those?” Juror B responded that he did not know whether his friends took those medications, but that he had heard of Kaletra. He added that he didn’t know much about the drug and that he had no personal experiences with it. In sum, Abbott’s counsel asked Juror B five questions, all regarding his knowledge of the drugs at issue in the litigation. Abbott’s counsel did not ask Juror B when he had taken either an Abbott or GSK medication, how long ago, which medication it was, or the purpose of the medication. He also 6 SMITHKLINE BEECHAM V. ABBOTT LABORATORIES

failed to ask any questions as to whether Juror B could decide the case fairly and impartially.

When the time came for peremptory challenges, Abbott exercised its first strike against Juror B. GSK’s counsel, Saveri, immediately raised a Batson challenge, and the following discussion ensued:

Mr. Saveri: Okay. So, you know, the first challenge, your honor, is a peremptory challenge of someone who is — who I think is or appears to be, could be homosexual. That’s use of the peremptory challenge in a discriminatory way.

The problem here, of course, your honor, is the litigation involves AIDS medication. The incidents [sic] of AIDS in the homosexual community is well-known, particularly gay men.

So with that challenge, Abbott wants to exclude from — it looks like Abbott wants to exclude from the pool anybody who is gay. So I am concerned about that. I wanted to raise it.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Strauder v. West Virginia
100 U.S. 303 (Supreme Court, 1880)
Brown v. Board of Education
347 U.S. 483 (Supreme Court, 1954)
Williamson v. Lee Optical of Oklahoma, Inc.
348 U.S. 483 (Supreme Court, 1955)
McGowan v. Maryland
366 U.S. 420 (Supreme Court, 1961)
Boutilier v. Immigration & Naturalization Service
387 U.S. 118 (Supreme Court, 1967)
United States Department of Agriculture v. Moreno
413 U.S. 528 (Supreme Court, 1973)
United States Railroad Retirement Board v. Fritz
449 U.S. 166 (Supreme Court, 1981)
Vasquez v. Hillery
474 U.S. 254 (Supreme Court, 1986)
Batson v. Kentucky
476 U.S. 79 (Supreme Court, 1986)
Gray v. Mississippi
481 U.S. 648 (Supreme Court, 1987)
Powers v. Ohio
499 U.S. 400 (Supreme Court, 1991)
Edmonson v. Leesville Concrete Co.
500 U.S. 614 (Supreme Court, 1991)
Romer v. Evans
517 U.S. 620 (Supreme Court, 1996)
Board of Trustees of Univ. of Ala. v. Garrett
531 U.S. 356 (Supreme Court, 2001)
Snyder v. Louisiana
552 U.S. 472 (Supreme Court, 2008)
Crittenden v. Ayers
624 F.3d 943 (Ninth Circuit, 2010)
United States v. Luis Gonzalez-Largo
436 F. App'x 819 (Ninth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Smithkline Beecham Corporation v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/smithkline-beecham-corporation-v-abbott-laboratori-ca9-2014.